Blood & Cancer

Hanny Al-Samkari, MD, joins the podcast to discuss thrombosis in COVID-19 and lung cancer patients as well as the use of bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT). Dr. Al-Samkari, of Massachusetts General Hospital, presented three studies on these topics at the virtual ISTH 2020 Congress. In this episode, Dr. Al-Samkari describes these studies to host David H. Henry, MD. Thrombosis, Bleeding, and the Effect of Anticoagulation on Survival in Critically Ill Patients with COVID-19 in the United States This 67-center study included 3,239 critically ill adults with COVID-19. The 14-day incidence of radiographically confirmed venous thromboembolism (VTE) was 6.3%. The 14-day incidence of strictly defined major bleeding was 2.8%. Patients who received therapeutic anticoagulation in the first 2 days of ICU admission had a similar risk of death at 28 days as patients who did not receive anticoagulation. Al-Samkari H et al. ISTH 2020, Abstract LB/CO01.2. https://bit.ly/3alvquE. An I